Dapagliflozin Effects on Epicardial Fat

Inclusion Criteria: * Type 2 diabetes, as defined by ADA criteria * HbA1c \< 8% measured at least 1 week prior to the study * BMI ≥27 kg/m2 * Pre-treatment with Metformin as monotherapy * Age \> 18 and \< 65 years old * Normal and stable hemodynamic status Exclusion Criteria: * Known contra-indications to Farxiga, in accordance with risks and safety information included in the latest updated Prescribing Information * Type 1 diabetes, as defined by American Diabetes Association (ADA) criteria * Insulin dependent or treated type 2 diabetes * Current use of other SGLT2 inhibitors, Glucagon Like Peptide -1 (GLP- 1) analogs or Dipeptidyl Peptidase 4 (DPP4) inhibitors * Glomerular Filtration Rate (GFR) \< 60 mL/min/1.73 m2 * Signs or symptoms of hypovolemia * Patients with poor glycemic control (HbA1c ≥ 8%) will be excluded to maximize long-term patient retention without need * History of diabetes ketoacidosis * Patients with active bladder cancer or with a prior history of bladder cancer * Acute or chronic infective, including genital mycotic infections * Clinical signs or symptoms of New York Heart Association (NYHA) class III-IV heart failure * Clinical or laboratory evidences of chronic active liver diseases * Acute or chronic infective diseases * Cancer or chemotherapy * Current use of systemic corticosteroids or in the 3 months prior this study * Known or suspected allergy to Dapagliflozin, excipients, or related products * Pregnant, breast-feeding or the intention of becoming pregnant * Females of childbearing potential who are not using adequate contraceptive methods